ATE393917T1 - Identifikation von therapeutische verbindungen. - Google Patents
Identifikation von therapeutische verbindungen.Info
- Publication number
- ATE393917T1 ATE393917T1 AT04717679T AT04717679T ATE393917T1 AT E393917 T1 ATE393917 T1 AT E393917T1 AT 04717679 T AT04717679 T AT 04717679T AT 04717679 T AT04717679 T AT 04717679T AT E393917 T1 ATE393917 T1 AT E393917T1
- Authority
- AT
- Austria
- Prior art keywords
- identification
- therapeutic compounds
- efficacy
- therapeutic agents
- potential therapeutic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0305153.9A GB0305153D0 (en) | 2003-03-07 | 2003-03-07 | Identification of therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393917T1 true ATE393917T1 (de) | 2008-05-15 |
Family
ID=9954251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04717679T ATE393917T1 (de) | 2003-03-07 | 2004-03-05 | Identifikation von therapeutische verbindungen. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070059773A1 (de) |
| EP (1) | EP1604211B1 (de) |
| JP (1) | JP4701330B2 (de) |
| AT (1) | ATE393917T1 (de) |
| AU (1) | AU2004217731B2 (de) |
| CA (1) | CA2514338A1 (de) |
| CY (1) | CY1108540T1 (de) |
| DE (1) | DE602004013431T2 (de) |
| DK (1) | DK1604211T3 (de) |
| ES (1) | ES2305741T3 (de) |
| GB (1) | GB0305153D0 (de) |
| PL (1) | PL1604211T3 (de) |
| PT (1) | PT1604211E (de) |
| SI (1) | SI1604211T1 (de) |
| WO (1) | WO2004079329A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| GB0305150D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| GB0305149D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| BRPI0508488A (pt) * | 2004-03-05 | 2007-07-31 | Cambridge Biotechnology Ltd | compostos terapêuticos |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| WO2007063538A1 (en) * | 2005-11-30 | 2007-06-07 | Can-Fite Biopharma Ltd. | Use of a3 adenosine receptor agonist in osteoarthritis treatment |
| RU2441875C2 (ru) | 2006-06-27 | 2012-02-10 | СиБиТи ДЕВЕЛОПМЕНТ ЛИМИТЕД | Терапевтические соединения |
| CA2654371A1 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Therapeutic compounds |
| EP2613277A1 (de) * | 2012-01-06 | 2013-07-10 | MathPharm GmbH | Verfahren und System zur Identifikation von Verbindungen, die einen Zielopioidrezeptor abhängig vom pH-Wert binden und vorzugsweise aktivieren |
| US10441541B2 (en) * | 2015-09-14 | 2019-10-15 | New York University | Methods and compositions for treating osteoarthritis and promoting cartilage formation |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2359536C2 (de) * | 1972-12-08 | 1984-08-02 | Takeda Chemical Industries, Ltd., Osaka | 2,6-Diaminonebularinderivate |
| JPS5461195A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | N2-substituted phenyl-2,6-diaminonebularin |
| JPS5461194A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | Preparation of n22substituted 2*66diaminonebularin |
| US4705758A (en) * | 1984-06-19 | 1987-11-10 | Warner-Lambert Company | Adenosine receptor assay and kit |
| US5104859A (en) * | 1985-09-24 | 1992-04-14 | Solimedco Aktiebolag | Continuous administration of adenosine to reduce pulmonary vascular resistance |
| US5231086A (en) * | 1985-09-24 | 1993-07-27 | Item Development Aktiebolag | Continuous administration adenosine to increase myocardial blood flow |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5140015A (en) * | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US5679650A (en) * | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| US6004945A (en) * | 1990-05-10 | 1999-12-21 | Fukunaga; Atsuo F. | Use of adenosine compounds to relieve pain |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US6180616B1 (en) * | 1990-05-10 | 2001-01-30 | Atsuo F. Fukunaga | Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function |
| US5683989A (en) * | 1993-12-17 | 1997-11-04 | Novo Nordisk A/S | Treatment of ischemias by administration of 2,N6 -substituted adenosines |
| US5596094A (en) * | 1994-05-26 | 1997-01-21 | Sandoz Ltd. | Process for preparing 2' -0- alkyl adenosine derivatives |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| IT1275420B (it) * | 1995-06-02 | 1997-08-05 | Schering Plough S P A | Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261 |
| US6110902A (en) * | 1997-06-23 | 2000-08-29 | Moehler; Hanns | Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine |
| GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
-
2003
- 2003-03-07 GB GBGB0305153.9A patent/GB0305153D0/en not_active Ceased
-
2004
- 2004-03-05 WO PCT/GB2004/000902 patent/WO2004079329A2/en active IP Right Grant
- 2004-03-05 SI SI200430770T patent/SI1604211T1/sl unknown
- 2004-03-05 AU AU2004217731A patent/AU2004217731B2/en not_active Ceased
- 2004-03-05 CA CA002514338A patent/CA2514338A1/en not_active Abandoned
- 2004-03-05 JP JP2006505911A patent/JP4701330B2/ja not_active Expired - Fee Related
- 2004-03-05 PT PT04717679T patent/PT1604211E/pt unknown
- 2004-03-05 ES ES04717679T patent/ES2305741T3/es not_active Expired - Lifetime
- 2004-03-05 DE DE602004013431T patent/DE602004013431T2/de not_active Expired - Lifetime
- 2004-03-05 AT AT04717679T patent/ATE393917T1/de not_active IP Right Cessation
- 2004-03-05 DK DK04717679T patent/DK1604211T3/da active
- 2004-03-05 US US10/547,462 patent/US20070059773A1/en not_active Abandoned
- 2004-03-05 EP EP04717679A patent/EP1604211B1/de not_active Expired - Lifetime
- 2004-03-05 PL PL04717679T patent/PL1604211T3/pl unknown
-
2008
- 2008-07-08 CY CY20081100713T patent/CY1108540T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB0305153D0 (en) | 2003-04-09 |
| AU2004217731A1 (en) | 2004-09-16 |
| CA2514338A1 (en) | 2004-09-16 |
| JP4701330B2 (ja) | 2011-06-15 |
| DE602004013431T2 (de) | 2009-06-25 |
| EP1604211A2 (de) | 2005-12-14 |
| PT1604211E (pt) | 2008-07-04 |
| ES2305741T3 (es) | 2008-11-01 |
| US20070059773A1 (en) | 2007-03-15 |
| DK1604211T3 (da) | 2008-09-08 |
| SI1604211T1 (sl) | 2008-10-31 |
| DE602004013431D1 (de) | 2008-06-12 |
| PL1604211T3 (pl) | 2008-09-30 |
| EP1604211B1 (de) | 2008-04-30 |
| AU2004217731B2 (en) | 2009-06-04 |
| WO2004079329A2 (en) | 2004-09-16 |
| WO2004079329A3 (en) | 2004-12-09 |
| JP2006519602A (ja) | 2006-08-31 |
| CY1108540T1 (el) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108540T1 (el) | Ταυτοποιηση θεραπευτικων ενωσεων | |
| BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| DE60329274D1 (de) | Kontrastmittel und verfahren zum imaging von naaldase oder psma | |
| DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| DK1651161T3 (da) | Farmaceutiske præparater og fremgangsmåder til at fremme sårheling | |
| CY1106256T1 (el) | Ιοντοφορητικη χορηγηση ροτιγκοτινης για τη θepαπεια της νοσου του parkinson | |
| BRPI0309665B8 (pt) | método para analisar uma preparação de alfagalactosidase a | |
| EA200801301A1 (ru) | ИНГИБИТОРЫ АКТИВНОСТИ Akt | |
| DE60236206D1 (de) | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| DE60219627D1 (de) | Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen | |
| NO20055211L (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
| EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
| EA201000491A1 (ru) | Аминометилзамещенные тетрациклиновые соединения | |
| CY1110923T1 (el) | Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων | |
| ATE538807T1 (de) | Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin | |
| DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| CY1107640T1 (el) | Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη | |
| CY1107531T1 (el) | Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου | |
| DE60310400D1 (de) | Botulinustoxine zur behandlung von priapismus | |
| MX2007005526A (es) | Tratamiento de mastitis con enrofloxacino. | |
| SE0301650D0 (sv) | Novel compounds | |
| CY1111432T1 (el) | Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5 | |
| ATE328000T1 (de) | Phospholipidester von clofarabin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1604211 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |